Related Experiment Video
Updated: Sep 24, 2025

Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
Do P2Y12 receptor inhibitors prescribed poststroke modify the risk of cognitive disorder or dementia? Protocol for a
Madeleine Hinwood1,2, Jenny Nyberg3, Lucy Leigh2
1School of Medicine and Public Health, The University of Newcastle, Callaghan, New South Wales, Australia Madeleine.Hinwood@newcastle.edu.au.
Introduction:
The target of a class of antiplatelet medicines, P2Y12R inhibitors, exists both on platelets and on brain immune cells (microglia). This protocol aims to describe a causal (based on a counterfactual model) approach for analysing whether P2Y12R inhibitors prescribed for secondary prevention poststroke may increase the risk of cognitive disorder or dementia via their actions on microglia, using real-world evidence.
Methods And Analysis:
This will be a cohort study nested within the Swedish National Health and Medical Registers, including all people with incident stroke from 2006 to 2016. We developed directed acyclic graphs to operationalise the causal research question considering potential time-independent and time-dependent confounding, using input from several experts. We developed a study protocol following the components of the target trial approach described by Hernan et al and describe the data structure that would be required in order to make a causal inference. We also describe the statistical approach required to derive the causal estimand associated with this important clinical question; that is, a time-to-event analysis for the development of cognitive disorder or dementia at 1, 2 and 5-year follow-up, based on approaches for competing events to account for the risk of all-cause mortality. Causal effect estimates and the precision in these estimates will be quantified.
Ethics And Dissemination:
This study has been approved by the Ethics Committee of the University of Gothenburg and Confidentiality Clearance at Statistics Sweden with Dnr 937-18, and an approved addendum with Dnr 2019-0157. The analysis and interpretation of the results will be heavily reliant on the structure, quality and potential for bias of the databases used. When we implement the protocol, we will consider and document any biases specific to the dataset and conduct appropriate sensitivity analyses. Findings will be disseminated to local stakeholders via conferences, and published in appropriate scientific journals.
Insights
This study proposes a causal analysis to investigate if P2Y12 receptor inhibitors, used after stroke, increase dementia risk by affecting brain microglia. The research uses Swedish health data to explore this potential link.
Area of Science:
- Neuroscience
- Pharmacology
- Epidemiology
Background:
- P2Y12 receptor inhibitors are prescribed for secondary stroke prevention.
- These inhibitors target P2Y12 receptors found on platelets and brain microglia.
- The potential impact of these drugs on cognitive function via microglia is not fully understood.
Purpose of the Study:
- To describe a causal approach for analyzing the risk of cognitive disorder or dementia associated with P2Y12 receptor inhibitors post-stroke.
- To investigate the role of microglia in mediating potential adverse cognitive effects of these antiplatelet medications.
- To utilize real-world evidence for causal inference in this clinical question.
Main Methods:
- A cohort study nested within Swedish National Health and Medical Registers (2006-2016).
- Utilizing directed acyclic graphs and the target trial approach for causal inference.
- Employing time-to-event analysis with competing risks for cognitive disorder or dementia development at 1, 2, and 5-year follow-ups.
Main Results:
- This section describes the planned analysis and data requirements for causal inference.
- Causal effect estimates and their precision will be quantified.
- Sensitivity analyses will be conducted to address potential biases in the real-world data.
Conclusions:
- The study protocol outlines a rigorous causal inference framework.
- It addresses a clinically relevant question regarding antiplatelet medication safety and cognitive health.
- Findings will inform clinical practice and future research on stroke recovery and dementia prevention.
More Related Videos
07:42Dual-Task Stroop Paradigm for Detecting Cognitive Deficits in High-Functioning Stroke Patients
Published on: December 16, 2022
03:26Author Spotlight: Advancing Stroke Research with Periorbital Doppler Monitoring of Regional Cerebral Blood Flow in Rodent Models
Published on: November 22, 2024
Related Concept Videos
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Alzheimer's Disease: Treatment
Dementia
The progression of dementia is generally gradual....